July 6, 2020 -- CSL Behring has enrolled the first patient in its phase clinical II study to assess the safety and efficacy of CSL312 (garadacimab, factor XIIa-inhibitory monoclonal antibody) to treat respiratory distress associated with COVID-19.
The multicenter, double-blind, placebo-controlled study will enroll approximately 124 adult patients with COVID-19. CSL312 will be administered intravenously in combination with standard-of-care treatments.
CSL312 inhibits the plasma protein, Factor XIIa, to prevent the molecular cascade leading to edema formation. It is also under clinical development as a once-monthly subcutaneous prophylactic treatment for attacks related to hereditary angioedema.
In addition to the study of CSL312, the company is also:
- Working with the Coalition for Epidemic Preparedness Innovations (CEPI), and the University of Queensland on a COVID-19 vaccine
- Working with the CoVIg-19 Plasma Alliance to develop anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin treatment
- Developing an anti-SARS-CoV-2 plasma product for the Australian market
- Partnering with SAB Biotherapeutics to develop a novel immunotherapy targeting COVID-19
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
